Novavax Inc. (NVAX)
Why Novavax (NVAX) Dipped More Than Broader Market Today
Novavax (NVAX) concluded the recent trading session at $8.19, signifying a -5.54% move from its prior day's close.
Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last?
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Novavax, Inc. ( NVAX ) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover semicap biotech in the U.S. It is my pleasure to have my next fireside chat with Novavax.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
Novavax, Inc. ( NVAX ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Nabeel Nissar - Jefferies LLC, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Eric Schmidt - Cantor Fitzgerald & Co., Research Division Christopher LoBianco - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Thomas Shrader - BTIG, LLC, Research Division Xun Lee - H.C.
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Novavax (NVAX) closed at $8.52, marking a -2.07% move from the previous day.
